Asciminib Hydrochloride
Brand name: Scemblix
Rank #408 of 500 drugs by total cost
$21.4M
Total Cost
830
Total Claims
$21.4M
Total Cost
59
Prescribers
$26K
Cost per Claim
0
Beneficiaries
846
30-Day Fills
$363K
Avg Cost/Provider
14
Avg Claims/Provider
About Asciminib Hydrochloride
Asciminib Hydrochloride (sold as Scemblix) was prescribed 830 times by 59 Medicare Part D providers in 2023, costing the program $21.4M. At $26K per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 405 | Tolterodine Tartrate (Tolterodine Tartrate Er) | $21.8M | 178,340 |
| 406 | Chlorthalidone (Chlorthalidone) | $21.8M | 966,780 |
| 407 | Ondansetron (Ondansetron Odt) | $21.5M | 1,261,950 |
| 408 | Asciminib Hydrochloride (Scemblix) | $21.4M | 830 |
| 409 | Cephalexin (Cephalexin) | $21.4M | 2,407,718 |
| 410 | Teprotumumab-Trbw (Tepezza) | $21.4M | 389 |
| 411 | Nystatin (Nystatin) | $21.4M | 908,177 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology